Are GLP-1 medications available across the EU?

Yes, Wegovy, Ozempic, Mounjaro, and Saxenda are EMA-authorized and available in all EU member states. However, national reimbursement varies significantly — Germany's public insurance (GKV) covers some weight loss medications, while other countries restrict coverage to diabetes only. Availability and pricing differ by country.

Can I order peptides online from another EU country?

For EMA-authorized medicines with a valid prescription — yes, under the cross-border healthcare directive (Directive 2011/24/EU). For unauthorized research peptides — generally no. The Falsified Medicines Directive restricts online sale of prescription medicines. National authorities enforce import restrictions. Online sellers based outside the EU face customs seizure.

Legal Disclaimer

This page provides general legal orientation for European Union, not legal advice. Regulations change frequently. Always verify current rules with EMA and consult a qualified professional.

Peptide Legal Status in European Union

Moderate

The EU regulates peptides through the EMA centralized procedure for biotechnology products and through national competent authorities for other medicines. GLP-1 agonists are EMA-approved via centralized procedure. National authorities (BfArM in Germany, ANSM in France, AEMPS in Spain, MEB in Netherlands) enforce at country level. Research peptides without marketing authorization face varying national enforcement.

Regulator

EMA (European Medicines Agency) — Official website

Key Facts

Regulatory Stance

moderate

Compounding Allowed

Yes

Telehealth Prescribing

Yes

Compounding Pharmacy Rules

Compounding (magistral/formula officinalis preparation) is permitted in most EU member states under national pharmacy laws, subject to GMP standards. Germany (Apothekenbetriebsordnung), France (Code de la Santé Publique), and the Netherlands allow pharmacy compounding for individual patients. Cross-border compounding is restricted. FDA Category 2 does not apply.

Telehealth Prescribing

Telehealth regulation varies by member state. Germany allows video consultation prescribing (Digitale-Versorgung-Gesetz). France requires at least one in-person consultation before telehealth prescribing. The Netherlands permits online prescribing with Beroepsvereniging-registered doctors. Cross-border telemedicine within the EU is legally complex and generally limited.

Peptide Categories in European Union

Approved

Semaglutide (Wegovy, Ozempic, Rybelsus), tirzepatide (Mounjaro), liraglutide (Saxenda) — all EMA-authorized through centralized procedure. National reimbursement (e.g., AMNOG in Germany, HAS in France) determines public coverage.

Research / Unapproved

BPC-157, TB-500, GHRP-2, GHRP-6 — no EMA marketing authorization. Legal status varies by member state. Germany classifies them as not marketable pharmaceuticals (nicht verkehrsfähige Arzneimittel) when sold for human use. France treats unauthorized medicines as illegal under Code de la Santé Publique. Enforcement intensity varies.

Banned / Restricted

Peptides without EU marketing authorization cannot be legally placed on the market for human use. WADA-prohibited peptides face additional sport anti-doping controls. The Falsified Medicines Directive imposes traceability and safety feature requirements on all prescription medicines.

Key Legislation

Directive 2001/83/EC (Community code relating to medicinal products)
Regulation (EC) No 726/2004 (EMA centralized procedure)
Falsified Medicines Directive 2011/62/EU
GDPR (impacts telehealth data handling)

Peptides in European Union: FAQ

Sources

Medical Disclaimer

This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.

Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.

No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.

Peptide Laws in Other Countries

United Kingdom Canada Australia Singapore United Arab Emirates New Zealand Germany Netherlands France Spain Hong Kong Japan South Korea

Get international legal updates

Stay informed when country-specific legal pages, routing guidance, and safety guidance change.

Free DownloadInternational Peptide Legal GuideGet our free quick reference covering peptide regulations across 14 countries — GLP-1 status, compounding rules, and telehealth access at a glance.PDF

No spam. Unsubscribe anytime.